Brief: Genocea Biosciences says GEN-009 Vaccine Demonstrates Best-In-Class Immune Responses To Atlas-Selected Neoantigens In Cancer Patients
03/06/2019 12:58
June 3 (Reuters) - Genocea Biosciences Inc GNCA.O :
* GENOCEA’S GEN-009 VACCINE DEMONSTRATES BEST-IN-CLASS
IMMUNE
RESPONSES TO ATLAS™-SELECTED NEOANTIGENS IN CANCER PATIENTS
* GENOCEA BIOSCIENCES INC - POST-VACCINATION T CELL
RESPONSES
DETECTED TO 91% OF VACCINE NEOANTIGENS
* GENOCEA BIOSCIENCES INC - CLINICAL RESULTS FROM ITS
ONGOING
PHASE 1/2A TRIAL FOR GEN-009, COMPANY'S LEAD NEOANTIGEN VACCINE
CANDIDATE
* GENOCEA BIOSCIENCES INC - GEN-009 HAS BEEN WELL TOLERATED
TO
DATE
Source text for Eikon: ID:nGNX8K3dXq
Further company coverage: GNCA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genocea Biosciences
See all newsBluebird, Chimerix, Clovis have under 6 months of cash left - Truist
Genocea Biosciences plunges as it winds down operations
Brief: Genocea Announces Wind Down Of Operations And Delisting From Nasdaq
Genocea Biosciences Inc reports results for the quarter ended in March - Earnings Summary
U.S. STOCKS ON THE MOVE-Oppenheimer Holdings, IES Holdings Inc, Avantor Inc